Condition: Atopic Dermatitis · Sponsor: Nora Mohamed Abdelrazik
This is a 12-week, single-arm, open-label pilot study to assess the safety and preliminary efficacy of oral roflumilast in patients aged 12 years and older with moderate-to-severe atopic dermatitis All participants, both male and female, will receive oral roflumilast starting at 250 mcg once daily for 10 days, followed by 500 mcg once daily for the remainder of the study. The primary outcome is the mean change in SCORAD (Scoring Atopic Dermatitis) score from baseline to Week 12. Secondary outcome include safety assessments, including treatment-emergent adverse events, serious adverse events, and laboratory abnormalities. Male and female participants will be analyzed as subgroups to explore potential differences in response or safety.
This description comes directly from the study's public registry record.
Nora Mohamed Abdelrazik, MD Dermatology · +201060291029 · noraeldarawany@gmail.com
Ahmed Ibrahim Ali, Master degree of Dermatology · +201011442104 · Ahmed.abdelhadi@med.suezuni.edu.eg
Always discuss trial participation with your own doctor first.
| Mansoura University Hospital | Al Mansurah, Dakahlia Governorate, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07297602